US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

First Trust SMID Growth Strength ETF

28.97

-0.1300-0.45%

Volume:906.00

Turnover:26.25K

Market Cap:28.97M

PE:- -

High:28.97

Open:28.97

Low:28.97

Close:29.10

Loading ...

Overview Company News Filings

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Press Release: Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Health Check: More, please! When record results are not good enough for expectant investors

Middle East healthcare expansion opens doors for ASX stocks

Travere Therapeutics: Strong Buy Rating Driven by Filspari’s $1 Billion Market Potential in FSGS

Rare opportunities – ASX health stocks tackling unmet medical needs

ASX healthcare leaders wear many hats in interconnected sector

Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally

Travere Therapeutics to submit sNDA for FILSPARI in FSGS

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Phase III Trials: It’s crunch time for these ASX health stocks

ASX Quarterly Health Wrap: EZZ hits an ace, ReNerve’s first quarterly since IPO

First paediatric patient recruited for Dimerix’s ACTION3 kidney disease drug trial

Dimerix Recruits First Paediatric Patient for Kidney Disease Drug Trial

MT Newswires Live

Road to 2025: DXB helping to treat kidney and respiratory disease

BUZZ-Guggenheim raises PT on Travere Therapeutics

Press Release: Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Press Release: Travere Therapeutics Provides Corporate Update and 2025 Outlook

Dimerix Exclusive Japan Licensing Deal 'Positive Suprise,' Euroz Hartleys Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/FSGS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FSGS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":28.97,"timestamp":1750177383540,"preClose":29.1,"halted":0,"volume":906,"delay":0,"floatShares":1000002,"shares":1000002,"eps":0,"marketStatus":"Trading","change":-0.13,"latestTime":"06-17 12:40:58 EDT","open":28.97,"high":28.97,"low":28.97,"amount":26246.010942,"amplitude":0,"askPrice":29.06,"askSize":223,"bidPrice":28.99,"bidSize":400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1750190400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":29.1,"sharesOutstanding":1000002,"nav":28.83,"aum":28830057.66,"dividendRate":0.026234,"bidAskSpread":0,"volumeRatio":1.151324},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","floatShares":1000002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.151324,"shares":1000002,"dividePrice":0.76,"high":28.97,"amplitude":0,"preClose":29.1,"low":28.97,"week52Low":24.39,"pbRate":"--","week52High":32.96,"institutionHeld":0,"latestPrice":28.97,"committee":0.284109,"eps":0,"divideRate":0.026234,"volume":906,"delay":0,"ttmEps":0,"open":28.97,"prevYearClose":29.7151,"prevWeekClose":28.797,"prevMonthClose":29.1468,"prevQuarterClose":27.34,"fiveDayClose":29.4952,"twentyDayClose":29.83,"sixtyDayClose":27.4162},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FSGS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514325974","title":"Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514325974","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514325974?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:05","pubTimestamp":1740744300,"startTime":"0","endTime":"0","summary":"Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI (pegcetacoplan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/28/3034648/0/en/Apellis-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGA","FSGS","BK4213"],"gpt_icon":0},{"id":"2514550806","title":"Ligand Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514550806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514550806?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033694/0/en/Ligand-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLM","CHMP","FSGS","BK4201","LU2237438978.USD","BK4588","BK4585","BK4011","SG9999001077.SGD","BK4548","EC","LU0053666078.USD","BK4156","BK4087"],"gpt_icon":0},{"id":"2514853378","title":"Press Release: Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514853378","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514853378?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:25","pubTimestamp":1740576300,"startTime":"0","endTime":"0","summary":"-- On track to announce the primary endpoint result from the atacicept. pivotal Phase 3 ORIGIN trial in IgA Nephropathy  in 2Q 2025; BLA. submission to the U.S. FDA for accelerated approval planned in 2H 2025. -- Expanded atacicept clinical development program in multiple autoimmune. planned FDA submission, and potential 2026 commercial launch of atacicept. \"Vera is poised to change the standard of care in autoimmune diseases with atacicept, our investigational therapy, beginning with IgA nephropathy. We are on track to announce the primary endpoint result of the ORIGIN Phase 3 study in the second quarter of this year. We look forward to submitting a Biologics License Application  for this potential best-in-class therapy in the second half of this year. We are grateful to the study investigators and participants for their ongoing and enthusiastic participation in this program,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"In addition, over the past year we have m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550221.USD","LU1430594728.SGD","BK4534","LU1244550577.SGD","LU1718418525.SGD","LU0942090050.USD","IE00BJTD4V19.USD","LU0868494617.USD","LU0868494708.USD","BK4585","BK4581","BK4209","BKV","LENZ","LU1585245621.USD","VERA","LU1244550494.USD","IE00BFSS7M15.SGD","BK4504","LU0256863811.USD","BK4139","IE0004445015.USD","PMN","TACI","BK4550","BK4588","MCD","IE00B7KXQ091.USD","LU0417517546.SGD","IE00BFSS8Q28.SGD","BK4566","BK4213","FSGS","IE00BJJMRX11.SGD","IE00BJJMRY28.SGD","LU2133065610.SGD","IE00BJTD4N35.SGD"],"gpt_icon":0},{"id":"2514364550","title":"Health Check: More, please! When record results are not good enough for expectant investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2514364550","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514364550?lang=en_us&edition=fundamental","pubTime":"2025-02-25 09:59","pubTimestamp":1740448741,"startTime":"0","endTime":"0","summary":"Polynovo and Avita Medical are victims of skittish market behaviour. Cyclopharm breathes easier after a good start with US sales. Control Bionics raises $2 million to rev up commercialisation","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1159049945-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1159049945-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/health-check-more-please-when-record-results-are-not-good-enough-for-expectant-investors/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["FSGS"],"gpt_icon":0},{"id":"2512787194","title":"Middle East healthcare expansion opens doors for ASX stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2512787194","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512787194?lang=en_us&edition=fundamental","pubTime":"2025-02-19 04:40","pubTimestamp":1739911203,"startTime":"0","endTime":"0","summary":"Middle East healthcare sector undergoing rapid expansion presenting opportunities for ASX-listed companies. ImpediMed has a distributor in Qatar for its SOZO bioimpedance spectroscopy  device for early detection and prevention of lymphoedema. The Middle East is emerging as a key market for Imricor, which received regulatory approval in Qatar and the Kingdom of Saudi Arabia in 2024","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1462549654-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1462549654-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/middle-east-healthcare-expansion-opens-doors-for-asx-stocks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4599","BK4533","IE00BBT3K403.USD","LU1066051498.USD","SG9999002232.USD","GCC","LU1883839398.USD","UAE","LU1894683348.USD","IE00BLSP4452.SGD","BK4585","LU0058720904.USD","LU0289739699.SGD","BIS","LU0122379950.USD","BK4550","LU1066053197.SGD","IE0002270589.USD","LU0306806265.USD","LU0225284248.USD","IE00B19Z3B42.SGD","LU0234572021.USD","SG9999013999.USD","LU0306807586.USD","SG9999002224.SGD","BK4007","LU0321505439.SGD","LU0985481810.HKD","SGXZ57979304.SGD","LU1894683264.USD","BK4534","IE00B19Z3581.USD","LU1023059063.AUD","LU0225771236.USD","BK4588","LU0868494617.USD","SG9999001176.USD","BK4592","LU0456855351.SGD","SG9999011175.SGD","LU0321505868.SGD","BK4581","IE000M9KFDE8.USD","BK4159","CAGR","LU0170899867.USD","BK4568","SG9999003800.SGD","FSGS"],"gpt_icon":1},{"id":"2511562672","title":"Travere Therapeutics: Strong Buy Rating Driven by Filspari’s $1 Billion Market Potential in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2511562672","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511562672?lang=en_us&edition=fundamental","pubTime":"2025-02-13 13:42","pubTimestamp":1739425348,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 11. Analyst Joseph...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/travere-therapeutics-strong-buy-rating-driven-by-filsparis-1-billion-market-potential-in-fsgs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/travere-therapeutics-strong-buy-rating-driven-by-filsparis-1-billion-market-potential-in-fsgs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","FSGS"],"gpt_icon":0},{"id":"2511301587","title":"Rare opportunities – ASX health stocks tackling unmet medical needs","url":"https://stock-news.laohu8.com/highlight/detail?id=2511301587","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511301587?lang=en_us&edition=fundamental","pubTime":"2025-02-13 04:05","pubTimestamp":1739390731,"startTime":"0","endTime":"0","summary":"There are significant incentives for pharmaceutical companies to develop treatments for rare diseases. Neurizon is focused on paediatric neurological disorders where there is inflammation, including rare diseases. Dimerix is focused on the rare kidney disease focal segmental glomerulosclerosis ","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-2190666371-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-2190666371-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/rare-opportunities-asx-health-stocks-tackling-unmet-medical-needs/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["ODD","BK4183","FSGS"],"gpt_icon":0},{"id":"2510359070","title":"ASX healthcare leaders wear many hats in interconnected sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2510359070","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510359070?lang=en_us&edition=fundamental","pubTime":"2025-02-12 04:05","pubTimestamp":1739304324,"startTime":"0","endTime":"0","summary":"ASX healthcare leaders are often involved in multiple companies or organisations. Syntara CEO Gary Philips believes seasoned executives can help develop the sector in Australia. Dimerix CEO and MD Dr Nina Webster has two other key positions supporting fellow biotechs","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1095759778-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1095759778-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/asx-healthcare-leaders-wear-many-hats-in-interconnected-sector/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["FSGS"],"gpt_icon":0},{"id":"2510779389","title":"Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2510779389","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510779389?lang=en_us&edition=fundamental","pubTime":"2025-02-11 21:43","pubTimestamp":1739281380,"startTime":"0","endTime":"0","summary":"Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug Filspari in focal segmental glomerulosclerosis, or FSGS, around the end of March.Shares of the San Diego company were recently up 9.8% at $23.16 in premarket trading.Travere said the filing will be based on existing data results from its Phase 3 and Phase 2 interventional studies of Filspari in the rare kidney disorder, which is a leading cause of kidney failure.The company said there are currently no FDA-approved treatments for FSGS, a condition in which the kidney's filtering units become scarred or hardened, leading to proteinuria , kidney failure and other complications.Travere said the results of its studies are in alignment with the recent findings of a group of experts that lowering proteinuria levels could be a better gauge of how well treatments for FSGS are working.Travere reported","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","BK4139","TVTX"],"gpt_icon":0},{"id":"2510388238","title":"Travere Therapeutics to submit sNDA for FILSPARI in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2510388238","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510388238?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:31","pubTimestamp":1739277092,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration and plans to submit a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-to-submit-snda-for-filspari-in-fsgs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-to-submit-snda-for-filspari-in-fsgs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FSGS","LENZ","TVTX"],"gpt_icon":0},{"id":"2510800340","title":"Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2510800340","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510800340?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:01","pubTimestamp":1739275260,"startTime":"0","endTime":"0","summary":"Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024045/0/en/Travere-Therapeutics-to-Submit-sNDA-for-FILSPARI-sparsentan-in-FSGS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","FSGS","BK4139"],"gpt_icon":0},{"id":"2507763670","title":"Phase III Trials: It’s crunch time for these ASX health stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2507763670","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507763670?lang=en_us&edition=fundamental","pubTime":"2025-01-29 23:07","pubTimestamp":1738163252,"startTime":"0","endTime":"0","summary":"Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25. Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25. Recce set to start trial assessing topical gel to treat diabetic foot infections in Indonesia","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/675-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/675-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/phase-iii-trials-its-crunch-time-for-these-asx-health-stocks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4139","LU2098885051.SGD","LU1923623000.USD","BK4162","BK4588","IE00BMPRXR70.SGD","BK4566","BK4543","LU0642271901.SGD","LU1242518931.SGD","IE00BDGV0183.EUR","IE00BMPRXN33.USD","LU1989764664.SGD","OPT","BK4534","BK4554","LU0889565833.HKD","AFL","IE00BVYPNQ40.USD","IE00BVYPNV92.GBP","LU1803068979.SGD","LU1951200564.SGD","IE00BGHQDM52.EUR","BK4575","LU1242518857.USD","LU0109392836.USD","LU0082616367.USD","IE00B42XCP33.USD","GFS","LU0289961442.SGD","LU1988902786.USD","III","FSGS","BK4134","LU0472753341.HKD","LU2458330243.SGD","LU1852331112.SGD","LU0823421333.USD","IE00BVYPNP33.GBP","BK4529","LU0198837287.USD","BK4573","LU0056508442.USD","LU0689626769.HKD","LU0823421416.USD","LU1880398554.USD","LU2264538146.SGD","LU0057025933.USD","IE0004445239.USD"],"gpt_icon":1},{"id":"2507857799","title":"ASX Quarterly Health Wrap: EZZ hits an ace, ReNerve’s first quarterly since IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507857799","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507857799?lang=en_us&edition=fundamental","pubTime":"2025-01-29 11:37","pubTimestamp":1738121839,"startTime":"0","endTime":"0","summary":"It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with news updates.Here, we wrap up report highlights from three standout stocks in the ASX health sector.EZZ Life Science . Receipts from customers totalled $15.8m for Q2 FY25, up 16.6% on pcp. Customer receipts up $2.2m in Q2 FY25 despite 3.9% reduction in advertising expenses compared to pcp. Operating cash flows rose to $1.6m, marking a 308% increase on pcp. Microba cash receipts of $3.87 million in Q2 FY25 up 109% on pcp with quarterly revenue of $4.43 million, up 102% on pcp. MetaPanel sales build in Australia through the Sonic Healthcare network withDecember a record sales month. MetaXplore sales started in UK through an early access program to key clinician accounts with test referral rates similar to Australia. Microba, which has technology for measuring the gut microbiome and was Morgan’s senior healthcare analyst Scott Power’s top stock pick last week, has released its Q2 FY25 re","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/1200x675-12-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/1200x675-12-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/asx-quarterly-health-wrap-ezz-hits-an-ace-renerves-first-quarterly-since-ipo/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["FSGS"],"gpt_icon":0},{"id":"2503989454","title":"First paediatric patient recruited for Dimerix’s ACTION3 kidney disease drug trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503989454","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503989454?lang=en_us&edition=fundamental","pubTime":"2025-01-16 11:06","pubTimestamp":1736996773,"startTime":"0","endTime":"0","summary":"First paediatric patient for Dimerix’s ACTION3 phase III clinical trial into a rare kidney disease has been recruited at a UK specialist site. A total of 19 specialist paediatric clinical sites across Argentina, Mexico, the UK and US will recruit patients to ACTION3. Paediatric development plan for lead drug DMX-200 aims to collect sufficient data for marketing approval in children aged over one. Paediatric patients aged from 12-17 to be included in current ACTION3 trial in patients with FSGS, in line with FDA and EMA advice. In silico  modelling, simulation, and extrapolation of paediatric data from ACTION3 to support confirmatory small open-label study in children aged","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-16-DXB-NM-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-16-DXB-NM-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/first-paediatric-patient-recruited-for-dimerixs-action3-kidney-disease-drug-trial/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["ARB","FSGS"],"gpt_icon":0},{"id":"2503989334","title":"Dimerix Recruits First Paediatric Patient for Kidney Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503989334","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503989334?lang=en_us&edition=fundamental","pubTime":"2025-01-16 10:04","pubTimestamp":1736993040,"startTime":"0","endTime":"0","summary":"Dimerix  recruited the first paediatric patient for the phase-three clinical trial for DMX-200, the company's drug candidate for kidney disease, according to a Thursday filing with the Australian bourse.The biopharmaceutical company is assessing the efficacy and safety of DMX-200 in patients with focal and segmental glomerulosclerosis , a rare disease that attacks the kidney's filtering units, per the filing.A total of 19 specialist paediatric clinical sites across Argentina, Mexico, the UK, and the US will recruit patients into the clinical trial.The biopharmaceutical company expects the blinded interim analysis in August.Dimerix's shares were up 2% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DXB.AU","BK7501","BK7067","FSGS"],"gpt_icon":0},{"id":"2503607979","title":"Road to 2025: DXB helping to treat kidney and respiratory disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2503607979","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503607979?lang=en_us&edition=fundamental","pubTime":"2025-01-16 09:13","pubTimestamp":1736989984,"startTime":"0","endTime":"0","summary":"Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.Dimerix  is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis , a second licensing deal and regulatory and ethics approval for their clinical trials.Tune in to find out what to look out for in 2025.This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Explore More   Investor Guide: Health & Biotech FY2025 featuring Tim Boreham","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/DMX-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/DMX-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/stockhead-tv/road-to-2025-dxb-helping-to-treat-kidney-and-respiratory-disease/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["FSGS","DXB"],"gpt_icon":0},{"id":"2503522179","title":"BUZZ-Guggenheim raises PT on Travere Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503522179","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503522179?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:47","pubTimestamp":1736858851,"startTime":"0","endTime":"0","summary":"** Brokerage Guggenheim raises PT on drug developer Travere Therapeutics    to $45 from $41   ** New PT represents a 142% upside to the stock's Monday close   ** TVTX's Filspari is an FDA-approved drug for the treatment of IgA nephropathy , a type of disease where a protein called IgA builds up in the kidneys, causing inflammation   ** On Monday, TVTX reported $50 mln in preliminary Filspari net product sales in 4Q 2024, which is \"somewhat above investor expectations\" of $45 mln, brokerage says   ** Brokerage says it is \"increasingly optimistic\" about Filspari's potential in IgAN and its potential label expansion to Focal Segmental Glomerulosclerosis , a type of kidney disease, representing a $2 bln peak sales opportunity in the U.S.   ** Brokerage forecasts annual U.S. Filspari sales for 2025 at $266 mln        ** TVTX gained ~82 in 2024 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","FSGS","PT","TVTX"],"gpt_icon":1},{"id":"2503451307","title":"Press Release: Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2503451307","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503451307?lang=en_us&edition=fundamental","pubTime":"2025-01-13 22:00","pubTimestamp":1736776800,"startTime":"0","endTime":"0","summary":"Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference. -- Reports $709 million in preliminary1 full-year 2024 U.S. net product. -- $611 million in SYFOVRE U.S. net product revenues, including. -- $98 million in EMPAVELI U.S. net product revenues, including. -- Expects submission of EMPAVELI sNDA for C3G and primary IC-MPGN in early. 2025; U.S. launch anticipated in 2H 2025, if approved. -- Plans initiation of Phase 3 studies of pegcetacoplan in two additional. -- Adam Townsend, chief operating officer, to depart Apellis in February;$410 million; projected revenues and cash expected to be sufficient to. \"SYFOVRE is the market-leading treatment for GA, with more than 120% net sales growth year-over-year and more than 510,000 injections administered,\" said Cedric Francois, M.D., Ph.D. \"We are entering 2025 with strong momentum and look to build on this by unlocking the blockbuster potential of SYFOVRE in GA and EMPAVELI across multi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","APLS","LU2264538146.SGD","LU2360106780.USD","LU1303367103.USD","R","BK4141","LU1880398554.USD","LU0390134368.USD","IE00B5949003.HKD","BK4566","LU1242518857.USD","LU0127658192.USD","LU1880398471.USD","LU2098885051.SGD","LU0198837287.USD","BK4575","LU1951200564.SGD","LU2054465674.USD","IE0009356076.USD","BK4139","BK4554","LU0889565833.HKD","LU1923623000.USD","LU1988902786.USD","LU1316542783.SGD","LU1852331112.SGD","LU0719512351.SGD","LU0823434740.USD","LU1064131342.USD","IE00BMPRXN33.USD","FSGS","LU0823434583.USD","LU1989764664.SGD","LU1951198990.SGD","LU1242518931.SGD","LU0082616367.USD","BK4137","BK4505","BK4512","BK4573","LU0823421333.USD","LU0979878070.USD","LU1803068979.SGD","BK4022","BK4532","IE0004445239.USD","LU2458330243.SGD","HCSG"],"gpt_icon":1},{"id":"2503308467","title":"Press Release: Travere Therapeutics Provides Corporate Update and 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2503308467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503308467?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:01","pubTimestamp":1736769660,"startTime":"0","endTime":"0","summary":"Received 693 new patient start forms for FILSPARI  in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter. sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025. Company remains on track to provide regulatory update on sparsentan in FSGS by its fourth quarter 2024 earnings call. SAN DIEGO, Jan. 13, 2025  -- Travere Therapeutics, Inc.,  today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2024 to be approximately $74 million. For the fiscal year 2024, the Company expects net product sales to be approximately $227 million. The Company ended 2024 with approximately $371 million in cash, cash equivalents, and marketable securities. The Company also provided an update on key corporate, clinical, and regulatory development initiatives, including anticipa","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4589","R","BK4232","BK4211","BK4139","BK4207","BK4588","CMA","TVTX","LENZ","BK4022","BK4585","FSGS"],"gpt_icon":0},{"id":"2502270057","title":"Dimerix Exclusive Japan Licensing Deal 'Positive Suprise,' Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2502270057","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502270057?lang=en_us&edition=fundamental","pubTime":"2025-01-09 13:41","pubTimestamp":1736401282,"startTime":"0","endTime":"0","summary":"Dimerix's  exclusive licensing agreement in Japan for its kidney disease drug candidate is a \"positive surprise,\" presenting additional value for the firm in the region, according to a Thursday note from Euroz Hartleys.Dimerix disclosed Tuesday that it entered into an exclusive development and license agreement worth a total of AU$107 million with Fuso Pharmaceutical Industries to develop and commercialize its drug candidate, DMX-200, to treat focal segmental glomerulosclerosis  in Japan.The Fuso licensing deal, Dimerix's third such deal, validates the ability of the firm's management to license across multiple territories, including in key markets like the US and Mainland China.Collectively, these licensing deals provide the company up to AU$458 million in upfront and potential milestone payments, as well as royalties on net sales.Importantly, Fuso, as a leading firm in the dialysis and renal/urology field, is well-positioned as an ideal partner for Dimerix in the region, the note sai","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","FSGS","BK7067","DXB.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FSGS\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FSGS","amount":0.3931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"FIRST TRUST EXCHANGE-TRADED FUND VI FIRST TRUST SMID GROWTH STRENGTH ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FSGS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":0.3931,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FSGS\",market:\"US\",delay:false,,,undefined,":{}}}